학술논문

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

Document Type

article

Author

Chertow, Glenn M; Appel, Gerald B; Block, Geoffrey A; Chin, Melanie P; Coyne, Daniel W; Goldsberry, Angie; Kalantar-Zadeh, Kamyar; Meyer, Colin J; Molitch, Mark E; Pergola, Pablo E; Raskin, Philip; Silva, Arnold L; Spinowitz, Bruce; Sprague, Stuart M; Rossing, Peter

Source

Journal of Diabetes and its Complications. 32(12)

Subject

Biomedical and Clinical Sciences
Clinical Sciences
Clinical Trials and Supportive Activities
Obesity
Clinical Research
Prevention
Kidney Disease
Diabetes
Nutrition
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Renal and urogenital
Metabolic and endocrine
Cancer
Aged
Blood Glucose
Body Weight
Diabetes Mellitus
Type 2
Diabetic Nephropathies
Disease Progression
Double-Blind Method
Female
Glomerular Filtration Rate
Glycated Hemoglobin
Humans
Male
Middle Aged
Oleanolic Acid
Renal Insufficiency
Chronic
Waist Circumference
Bardoxolone methyl
Chronic kidney disease
Metabolic effects
HbA(1c)
Randomized clinical trial
Endocrinology & Metabolism
Clinical sciences

Language

Abstract

AimsObesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.MethodsEligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to

Online Access

Open Access (eScholarship) Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송